TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation.
We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health Development, Tokyo, Japan.
Kenichiro
K
Kobayashi
Naoyuki
N
Miyagawa
Kazumasa
K
Mitsui
Masaki
M
Matsuoka
Yasuko
Y
Kojima
Hiroyuki
H
Takahashi
Kaori
K
Ootsubo
Junichi
J
Nagai
Hitomi
H
Ueno
Takeshi
T
Ishibashi
Sara
S
Sultana
Yoko
Y
Okada
Shingo
S
Akimoto
Hajime
H
Okita
Kimikazu
K
Matsumoto
Hiroaki
H
Goto
Nobutaka
N
Kiyokawa
Akira
A
Ohara
D002648:Child; D000069439:Dasatinib; D006801:Humans; D008297:Male; D018365:Neoplasm, Residual; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000235:genetics*; D012097:Repressor Proteins; D013844:Thiazoles / Q000627:therapeutic use*; D014157:Transcription Factors / Q000235:genetics*; D014178:Translocation, Genetic
C501309:ATF7IP protein, human; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D012097:Repressor Proteins; D013844:Thiazoles; D014157:Transcription Factors; D011505:Protein-Tyrosine Kinases; D020797:Receptor, Platelet-Derived Growth Factor beta; D000069439:Dasatinib
MRD; PDGFRB fusion; Ph-like ALL; TKI; genomic PCR